
Anne Y Saiki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9054528/publications.pdf

Version: 2024-02-01



ANNE V SAIVI

#	Article	IF	CITATIONS
1	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575, 217-223.	13.7	1,375
2	Discovery of a Covalent Inhibitor of KRAS ^{G12C} (AMG 510) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry, 2020, 63, 52-65.	2.9	403
3	Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development. Journal of Medicinal Chemistry, 2014, 57, 1454-1472.	2.9	223
4	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	13.7	183
5	The Role of MDM2 Amplification and Overexpression in Tumorigenesis. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026336.	2.9	158
6	Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction. Journal of Medicinal Chemistry, 2012, 55, 4936-4954.	2.9	151
7	The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Molecular Cancer Therapeutics, 2015, 14, 649-658.	1.9	112
8	Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction. Journal of Medicinal Chemistry, 2014, 57, 2472-2488.	2.9	76
9	Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 4053-4070.	2.9	71
10	Discovery of <i>N</i> -(1-Acryloylazetidin-3-yl)-2-(1 <i>H</i> -indol-1-yl)acetamides as Covalent Inhibitors of KRAS ^{G12C} . ACS Medicinal Chemistry Letters, 2019, 10, 1302-1308.	1.3	66
11	Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres. Journal of Medicinal Chemistry, 2014, 57, 2963-2988.	2.9	48
12	MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways. Oncotarget, 2014, 5, 2030-2043.	0.8	45
13	Discovery of AM-7209, a Potent and Selective 4-Amidobenzoic Acid Inhibitor of the MDM2–p53 Interaction. Journal of Medicinal Chemistry, 2014, 57, 10499-10511.	2.9	42
14	Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2752-2755.	1.0	37
15	Identifying the determinants of response to MDM2 inhibition. Oncotarget, 2015, 6, 7701-7712.	0.8	35
16	Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2–p53 Interaction. ACS Medicinal Chemistry Letters, 2014, 5, 894-899.	1.3	25
17	From Bacterial Genomes to Novel Antibacterial Agents: Discovery, Characterization, and Antibacterial Activity of Compounds that Bind to HI0065 (YjeE) from Haemophilus influenzae. Chemical Biology and Drug Design, 2007, 69, 395-404.	1.5	17
18	Abstract 4484: Discovery and in vitro characterization of AMG 510–a potent and selective covalent small-molecule inhibitor of KRASG12C. , 2019, , .		9

ANNE Y SAIKI

#	Article	IF	CITATIONS
19	Abstract 3090: <i>In vivo</i> characterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models. Cancer Research, 2019, 79, 3090-3090.	0.4	5
20	Abstract 4455: Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12Cfor the treatment of solid tumors. , 2019, , .		4
21	Abstract 1285: <i>In vitro</i> characterization of sotorasib and other RAS â€~His95-groove' binders and investigation of resistance mechanisms. Cancer Research, 2021, 81, 1285-1285.	0.4	2
22	Abstract 1057: Combination of the KRASG12Cinhibitor sotorasib with targeted agents improves anti-tumor efficacy inKRAS p.G12Ccancer models. , 2021, , .		0